Evidence map›Paper›PMID 30176179›Full record

Observational studyJournal of the European Academy of Dermatology and Venereology : JEADV2019

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.

M Maurer, K Bork, I Martinez-Saguer, E Aygören-Pürsün, J Botha, I Andresen, M Magerl

Registry-linked trialOpen access · hybridAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the European Academy of Dermatology and Venereology : JEADV, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01034969 (Icatibant Outcome Survey), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01034969 completednot on this map

Icatibant Outcome Survey (IOS) Registry

TypeobservationalSponsorShireRan2009 to 2024Enrolled1,761ConditionsHereditary Angioedema (HAE)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

M MaurerDepartment of Dermatology and Allergy, Allergy Center Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
K BorkDepartment of Dermatology, Johannes Gutenberg University, Mainz, Germany.
I Martinez-SaguerHZRM Hemophilia Center Rhine Main, Mörfelden-Walldorf, Germany.
E Aygören-PürsünDepartment for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
J BothaShire, Zug, Switzerland.
I AndresenShire, Zug, Switzerland.
M MagerlDepartment of Dermatology and Allergy, Allergy Center Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEJohannes Gutenberg University Mainz · DEUniversity Hospital Frankfurt · DE

Funding

Shire GmbH, Zug, Switzerland
6 · The paper itself

Abstract

backgroundThe Icatibant Outcome Survey (IOS; NCT01034969) is a Shire-sponsored, international, observational study monitoring the safety and effectiveness of icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-INH).

objectiveTo report IOS data comparing demographic and icatibant treatment outcomes in patients with HAE-C1-INH from Germany to HAE-C1-INH patients from 11 other IOS countries.

methodsA descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE-C1-INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom (n = 592, July 2009-January 2017). Icatibant treatment outcomes were retrieved from patients with complete attack outcome data for time to treatment, time to resolution and attack duration (160 attacks in 42 German patients and 1442 attacks in 251 patients from other IOS countries).

resultsGerman patients reported significantly fewer severe/very severe attacks (38.7% vs. 57.5%, respectively; P < 0.001). The proportion of attacks treated with a single icatibant injection was significantly higher in German patients (97.1% vs. 91.6%, P = 0.0003). The median time to treatment (0.0 h vs. 1.5 h), time to resolution (3.0 h vs. 7.0 h) and attack duration (4.3 h vs. 10.5 h) in German patients vs. other IOS countries were all significantly shorter (all P < 0.0001). No meaningful differences were identified between patients from Germany and other countries with regard to sex, median age at enrolment, median age at symptom onset and median age at diagnosis.

conclusionGerman IOS patients share similar demographic characteristics to patients from other IOS countries yet treat their attacks with icatibant significantly earlier and have markedly fewer severe or very severe attacks. Factors including regional access to and availability of icatibant may drive these outcomes and warrant further investigation.

Indexed as

Symptom Flare UpAdultAngioedemas, HereditaryBradykininBradykinin B2 Receptor AntagonistsFemaleGermanyHealth SurveysHumansMaleMiddle AgedRetrospective StudiesTime FactorsTime-to-TreatmentBradykininBradykinin B2 Receptor Antagonistsicatibant

Identifiers

PMID30176179
PMCPMC6587717
OpenAlexW2890876039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.